In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Poniard Pharmaceuticals, Inc.

Latest From Poniard Pharmaceuticals, Inc.

China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer

CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.

China Vaccines

Chinese Biotech Financing Rebounds But Mega Deals Missing

Ten Chinese biotechs raised at least a combined $221m in venture capital and private equity deals after the turn of the year.

China Financing

Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing

Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.

Deal Watch Business Strategies

Hemab Raises $135m To Advance Clinical Strategy In Bleeding And Thrombotic Disorders

Hemab’s series B financing will fund its lead program, currently in Phase I/II for Glanzmann thrombasthenia, as it moves into pivotal testing plus at least one other asset heading into the clinic.

Financing Blood & Coagulation Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • NeoRx
UsernamePublicRestriction

Register